WHO ICTRP trial
A Clinical study to investigate if rVA576 is safe and has an effect on patients…
EUCTR2017-002836-18-NL · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2017-002836-18-NL |
|---|---|
| Public title | A Clinical study to investigate if rVA576 is safe and has an effect on patients who have mild or moderate Bullous Pemphigoid (a blistering disorder where the skin forms tense blisters) |
| Scientific title | A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects |
| Primary sponsor | Akari Therapeutics Plc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Germany;Netherlands |
| Conditions | Mild to Moderate Bullous Pemphigoid MedDRA version: 21.1 Level: LLT Classification code 10006567 Term: Bullous pemphigoid System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] |
| Interventions | Product Name: rVA576 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: rVA576 Current Sponsor code: rVA576 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18- |
| Registration date | Jan 24, 2018 |
| Target size | 9 |
| Secondary IDs | AK801 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: